Achilles Therapeutics plc (NASDAQ:ACHL) Sees Significant Drop in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 136,700 shares, a decrease of 36.6% from the November 15th total of 215,700 shares. Based on an average daily trading volume, of 673,800 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.4% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Achilles Therapeutics stock. BML Capital Management LLC increased its holdings in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 4,100,002 shares of the company’s stock after purchasing an additional 3,474,828 shares during the period. Achilles Therapeutics accounts for approximately 2.5% of BML Capital Management LLC’s holdings, making the stock its 11th largest position. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 at the end of the most recent quarter. 56.38% of the stock is currently owned by hedge funds and other institutional investors.

Achilles Therapeutics Trading Down 2.9 %

NASDAQ:ACHL opened at $0.99 on Friday. The stock has a market capitalization of $40.69 million, a PE ratio of -0.60 and a beta of 1.37. Achilles Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.76. The firm has a fifty day simple moving average of $1.03 and a 200 day simple moving average of $0.90.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.